Previous Study: CIRG/TORI 010
Next Study: TRIO012
Studies & Results
TORI L-03
Phase II erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer.
Presentations
AACR Annual Meeting , 2013
Garon EB, Siegfried JM, Dubinett SM, et al
Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
Publications
Garon EB, Siegfried JM, Dubinett SM, et al: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
AACR 104th Annual Meeting, 2013
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
AACR Annual Meeting , 2013
Garon EB, Siegfried JM, Dubinett SM, et al
Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
Publications
Garon EB, Siegfried JM, Dubinett SM, et al: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). AACR 104th Annual Meeting, 2013
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org